Is Antioxidant Therapy a Viable Alternative for Mild Cognitive Impairment? Examination of the Evidence
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Therapeutic interventions for the prodromal stages of dementia are currently being sought with a view to delaying if not preventing disease onset. Uncertainty as to whether cognitive disorder in a given individual will progress towards dementia and adverse drug side effects has led to hesitancy on the part of drug regulators to instigate preventive pharmacotherapies. In this context, antioxidant therapies may provide a low-risk alternative, targeting very early biological changes. While a growing body of knowledge demonstrates both the importance of oxidative stress in the aetiology of dementia and the efficacy of antioxidant treatment in animal and cellular models, studies in humans are presently inconclusive. While some antioxidants, notably flavonoid- or vitamin-rich diets, appear to lower the relative risk for Alzheimer’s disease in humans in observational studies, these results must be interpreted in the light of the biological complexity of the relationship between oxidative stress and neurodegeneration, and the methodological and theoretical shortcomings of studies conducted to date. A clearer understanding of these factors will assist in the interpretation of the results of the intervention studies which are now being undertaken; these studies being the only current means of establishing efficacy for preventive drug treatment of Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“thus concluded that there presently exists ‘insufficient evidence of efficacy of vitamin E in the treatment of people with AD’.More recently, a larger 3-year RCT was performed by the same research group, including 769 patients with MCI randomly assigned to receive 2,000 IU vitamin E, 10 mg donepezil or placebo daily.…”
Background(2005) · JAMA · doi:10.1001/jama.293.11.1338 · Cited by 1,209 · cited 1×
“The published RCT focused, however, on persons with existing coronary disease (secondary prevention) and gave inconsistent results. Thus the weight of evidence is against short-term benefit from vitamin E supplements among patients with cardiovascular disease being treated with multiple pharmacologic agents. The long-…”
BackgroundLee, I.-M., Cook, N. R., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.56 · Cited by 1,137
Dietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
Le Bars, P. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550160047037 · Cited by 966
Vitamin C exhibits pro-oxidant properties
Podmore, I. D., Griffiths, H. R., Herbert, K. E., Mistry, N., Mistry, P., & Lunec, J. (1998) · Nature · doi:10.1038/33308 · Cited by 800 · cited 1×
“Ascorbic acid alone could exacerbate iron-dependent radical reactions in the brain and vitamin C (500 mg/day) may act as a pro-oxidant in the body [”
BackgroundHensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S. P., Wu, J. F., Carney, J. M., et al. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65052146.x · Cited by 779
Morris, M. C. (2002) · JAMA · doi:10.1001/jama.287.24.3230 · Cited by 678
Halliwell, B. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02075-4 · Cited by 655
Abramov, A. Y., Canevari, L., & Duchen, M. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4042-03.2004 · Cited by 587
Lyras, L., Cairns, N. J., Jenner, A., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052061.x · Cited by 531
Diabetes, impaired fasting glucose, and development of cognitive impairment in older women
Yaffe, K., Blackwell, T., Kanaya, A. M., Davidowitz, N., Barrett-Connor, E., & Krueger, K. (2004) · Neurology · doi:10.1212/01.wnl.0000134666.64593.ba · Cited by 520
Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease
Marcus, D. L., Thomas, C., Rodriguez, C., Simberkoff, K., Tsai, J. S., Strafaci, J. A., & Freedman, M. L. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6750 · Cited by 513
Polyunsaturated Fatty Acids, Antioxidants, and Cognitive Function in Very Old Men
Kalmijn, S., Feskens, E. J. M., Launer, L. J., & Kromhout, D. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009029 · Cited by 453
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414 · cited 1×
“Thus, while the principal action of antioxidants is generally considered to be their ability to protect cells from lesions induced by free radicals, they also appear to have a more general impact on cell regulation, notably in relation to mitochondrial energy metabolism, cell signalling and gene expression. Biological…”
BackgroundIncreased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
Melatonin Prevents Death of Neuroblastoma Cells Exposed to the Alzheimer Amyloid Peptide
Pappolla, M. A., Sos, M., Omar, R. A., Bick, R. J., Hickson-Bick, D. L. M., Reiter, R. J., Efthimiopoulos, S., & Robakis, N. K. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01683.1997 · Cited by 359
Vitamin E and Cognitive Decline in Older Persons
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., & Wilson, R. S. (2002) · Archives of Neurology · doi:10.1001/archneur.59.7.1125 · Cited by 346
Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease
Morris, M. C., Beckett, L. A., Scherr, P. A., Hebert, L. E., Bennett, D. A., Field, T. S., & Evans, D. A. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199809000-00001 · Cited by 332
Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change
Morris, M. C., Evans, D. A., Tangney, C. C., Bienias, J. L., Wilson, R. S., Aggarwal, N. T., & Scherr, P. A. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn.81.2.508 · Cited by 302
Jama, J. W., Launer, L. J., Witteman, J. C. M., den Breeijen, J. H., Breteler, M. M. B., Grobbee, D. E., & Hofman, A. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008922 · Cited by 252
Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease
Adair, J. C., Knoefel, J. E., & Morgan, N. (2001) · Neurology · doi:10.1212/wnl.57.8.1515 · Cited by 240
Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease
Foy, C. J. (1999) · QJM · doi:10.1093/qjmed/92.1.39 · Cited by 235
Laurin, D. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh124 · Cited by 231 · cited 1×
“A recent study found no association between midlife intake and risk of late-onset AD 30 years later, however, dietary intake was only evaluated at baseline [”
BackgroundLymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease
Mecocci, P. (2002) · Archives of Neurology · doi:10.1001/archneur.59.5.794 · Cited by 229
Treatment of Alzheimer’s Disease with Clioquinol
Regland, B., Lehmann, W., Abedini, I., Blennow, K., Jonsson, M., Karlsson, I., Sjögren, M., Wallin, A., Xilinas, M., & Gottfries, C.-G. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051288 · Cited by 220
Bruce, A. J., Malfroy, B., & Baudry, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2312 · Cited by 216
High-dose antioxidant supplements and cognitive function in community-dwelling elderly women
Grodstein, F., Chen, J., & Willett, W. C. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.4.975 · Cited by 214
Alpha-lipoic acid as a new treatment option for Azheimer type dementia
Hager, K., Marahrens, A., Kenklies, M., Riederer, P., & Münch, G. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00104-2 · Cited by 188
F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease
Nourooz‐Zadeh, J., Liu, E. H. C., Yhlen, B., Änggåard, E. E., & Halliwell, B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720734.x · Cited by 187
Gutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162
Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156
A Controlled Study of 2 Doses of Idebenone in the Treatment of Alzheimer’s Disease
Weyer, G., Babej-Dölle, R. M., Hadler, D., Hofmann, S., & Herrmann, W. M. (2008) · Neuropsychobiology · doi:10.1159/000119366 · Cited by 120
Robson, K. J. H., Lehmann, D. J., Wimhurst, V. L. C., Livesey, K. J., Combrinck, M., Merryweather-Clarke, A. T., Warden, D. R., & Smith, A. D. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015552 · Cited by 120
Dementia and Alzheimer's Disease in Community-Dwelling Elders Taking Vitamin C and/or Vitamin E
Fillenbaum, G. G., Kuchibhatla, M. N., Hanlon, J. T., Artz, M. B., Pieper, C. F., Schmader, K. E., Dysken, M. W., & Gray, S. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g280 · Cited by 113
Supplemental Use of Antioxidant Vitamins and Subsequent Risk of Cognitive Decline and Dementia
Maxwell, C. J., Hicks, M. S., Hogan, D. B., Basran, J., & Ebly, E. M. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000085074 · Cited by 105 · cited 1×
“] found a positive association with specific cognitive tests (short-term memory and verbal fluency), and the 2 others showed a link with global cognitive functioning [ ,”
BackgroundSchmidt, R., Hayn, M., Reinhart, B., Roob, G., Schmidt, H., Schumacher, M., Watzinger, N., & Launer, L. J. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb06008.x · Cited by 96
Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study
Cherubini, A., Martin, A., Andres-Lacueva, C., Di Iorio, A., Lamponi, M., Mecocci, P., Bartali, B., Corsi, A., Senin, U., & Ferrucci, L. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.09.002 · Cited by 94
Mendelsohn, A. B., Belle, S. H., Stoehr, G. P., & Ganguli, M. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009556 · Cited by 88
Enhanced brain levels of 8,12- iso -iPF 2α -VI differentiate AD from frontotemporal dementia
Yao, Y., Zhukareva, V., Sung, S., Clark, C. M., Rokach, J., Lee, V. M.-Y., Trojanowski, J. Q., & Praticò, D. (2003) · Neurology · doi:10.1212/01.wnl.0000070185.02546.5d · Cited by 86
Gutzmann, H., Kühl, K.-P., Hadler, D., & Rapp, M. A. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-19833 · Cited by 85
Dietary antioxidant intake and cognitive performance in middle-aged adults
Peacock, J. M., Folsom, A. R., Knopman, D. S., Mosley, T. H., Goff, D. C., & Szklo, M. (2000) · Public Health Nutrition · doi:10.1017/s1368980000000380 · Cited by 33
Inflammatory Proteins in Plasma and the Risk of Dementia: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.668 · Cited by 10
Cited by
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Diet and Alzheimer’s disease risk factors or prevention: the current evidence
Solfrizzi, V., Panza, F., Frisardi, V., Seripa, D., Logroscino, G., Imbimbo, B. P., & Pilotto, A. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.56 · Cited by 297
Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research
Seigers, R., & Fardell, J. E. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.09.006 · Cited by 266
Nurk, E., Refsum, H., Drevon, C. A., Tell, G. S., Nygaard, H. A., Engedal, K., & Smith, A. D. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.095182 · Cited by 261
Samieri, C., Féart, C., Letenneur, L., Dartigues, J.-F., Pérès, K., Auriacombe, S., Peuchant, E., Delcourt, C., & Barberger-Gateau, P. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.3.714 · Cited by 184
Metadata
- Authors
- Ancelin, M.-L., Christen, Y., & Ritchie, K.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 24
- Issue
- 1
- Pages
- 1-19
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2018828301
- Cited by
- 50
- References
- 47
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.